A comparative study of four cell-free DNA assays for detecting circulating tumor DNA in early breast cancer

A comparative study of four cell-free DNA assays for detecting circulating tumor DNA in early breast cancer

Abstract Early prediction of the response to neoadjuvant chemotherapy (NAC) enables tailoring treatment strategies to the specific needs of individual breast cancer patients. Circulating tumor DNA (ctDNA) has shown to be a prognostic factor for response on NAC during treatment. However, at this poin...

Full description

Saved in:
Bibliographic Details
Main Authors: Charlotta V. Mulder, Elisabeth M. Jongbloed, Marte C. Liefaard, Stavros Makrodimitris, Daan M. Hazelaar, Corine M. Beaufort, Vanja de Weerd, Lennart Mulder, Carolien H.M. van Deurzen, Gabe S. Sonke, Agnes Jager, Saskia M. Wilting, John W.M. Martens, Maurice P.H.M. Jansen, Esther H. Lips
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Breast Cancer Research
Subjects:
Early breast cancer
Neoadjuvant treatment
Circulating tumor DNA
Online Access:https://doi.org/10.1186/s13058-025-02077-8
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Early prediction of the response to neoadjuvant chemotherapy (NAC) enables tailoring treatment strategies to the specific needs of individual breast cancer patients. Circulating tumor DNA (ctDNA) has shown to be a prognostic factor for response on NAC during treatment. However, at this point in time mostly tumor-informed ctDNA detection methods are used which are costly, have relatively long turnaround times and are subsequently potentially less feasible for widespread clinical application. In this study, we investigated four tumor-agnostic methods to determine their ability to accurately detect circulating tumor DNA (ctDNA) at baseline. These methods were the Oncomine Breast cell free DNA (cfDNA) NGS panel, the LINE-1 sequencing assay mFAST-SeqS, shallow whole genome sequencing and the genome-wide methylation profiling assay MeD-Seq. In total 40 patients with triple negative or luminal B breast cancer were included and cell free DNA (cfDNA) from plasma before the start of NAC was analyzed with the four assays. We detected ctDNA in 3/24 (12.5%) patients with Oncomine, 5/40 (12.5%) with mFast-SeqS, 3/40 (7.7%) with low pass shallow WGS and 23/40 with MeD-Seq (57.5%). When all methods were combined ctDNA was detected in 65% of patients. In conclusion, we demonstrated that tumor agnostic methods, in particular MeD-Seq, can detect ctDNA in a fraction of the patients with early breast cancer, but further optimization is needed to reach the potential currently demonstrated by tumor-informed methods.
ISSN:1465-542X

Similar Items